Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aztreonam.

A R Tunkel1, W M Scheld

  • 1Department of Internal Medicine, University of Virginia School of Medicine, Charlottesville.

Infection Control and Hospital Epidemiology
|September 1, 1990
PubMed
Summary
This summary is machine-generated.

Aztreonam is a monobactam antibiotic effective against aerobic gram-negative bacilli. It offers a favorable safety profile, making it suitable for patients with penicillin or cephalosporin allergies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013
Same author

Societal costs versus savings from wild-card patent extension legislation to spur critically needed antibiotic development.

Infection·2007
Same author

A pseudo-outbreak of nosocomial infections associated with the introduction of an antibiotic management programme.

The Journal of hospital infection·2003
Same author

Antibiotics for severe chronic obstructive pulmonary disease.

Lancet (London, England)·2002
Same author

Rigid nasal endoscopy versus sinus puncture and aspiration for microbiologic documentation of acute bacterial maxillary sinusitis.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2001
Same author

Cyclic AMP-dependent inhibition of human neutrophil oxidative activity by substituted 2-propynylcyclohexyl adenosine A(2A) receptor agonists.

British journal of pharmacology·2001
Same journal

Integrating patient in-hospital transfer patterns into automated outbreak detection systems: a single-center retrospective study.

Infection control and hospital epidemiology·2026
Same journal

Colonization with multidrug-resistant organisms (MDROs) including <i>Candidozyma auris</i> among residents in ventilator-designated versus non-ventilator-designated beds at skilled nursing facilities (SNFs).

Infection control and hospital epidemiology·2026
Same journal

Exploring unconventional antimicrobial stewardship models: options beyond traditional prospective audit and feedback.

Infection control and hospital epidemiology·2026
Same journal

Rectal versus groin screening for multidrug-resistant organisms: pathogen-specific diagnostic yield in a tertiary-care hospital.

Infection control and hospital epidemiology·2026
Same journal

Comparing rapid molecular and culture methods for detecting fungal contamination in healthcare environments.

Infection control and hospital epidemiology·2026
Same journal

Prospective validation and implementation of a model to identify patients with carbapenem-resistant Enterobacterales (CRE) carriage on admission to acute care hospitals.

Infection control and hospital epidemiology·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Antibiotic Therapy

Background:

  • Aztreonam is the first commercially available monobactam antibiotic.
  • It exhibits broad-spectrum activity against aerobic gram-negative bacilli.
  • Its pharmacokinetic profile allows for convenient dosing schedules.

Purpose of the Study:

  • To review the clinical utility and safety of aztreonam.
  • To highlight its efficacy in various infections caused by gram-negative bacteria.
  • To assess its role in empiric antibiotic therapy.

Main Methods:

  • Review of existing clinical data and studies on aztreonam.
  • Analysis of antimicrobial spectrum, including minimum inhibitory concentrations (MICs).
  • Evaluation of adverse reaction profiles and cross-reactivity with other beta-lactam antibiotics.

Related Experiment Videos

Main Results:

  • Aztreonam demonstrates excellent activity against Enterobacteriaceae (MIC ≤ 2 µg/ml) and Pseudomonas aeruginosa (MIC ≤ 16 µg/ml).
  • It is effective in treating diverse infections, including urinary tract, respiratory, blood, and skin/bone infections.
  • Adverse reactions are infrequent, and it is well-tolerated in patients with penicillin and cephalosporin allergies.
  • Efficacy is comparable or superior to aminoglycosides.

Conclusions:

  • Aztreonam is a valuable antibiotic for treating gram-negative infections.
  • Its safety profile and activity make it a suitable option, especially in penicillin-allergic patients.
  • It can be used as monotherapy for specific gram-negative urinary tract infections and in combination regimens for broader coverage.